Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $51

Futu NewsNov 15 21:31 · Ratings

Rocket Pharmaceuticals to Present Updated Data From the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions

BusinesswireNov 13 05:01

BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating

Futu NewsNov 12 22:31 · Ratings

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target

BenzingaNov 12 05:50 · Ratings

Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $51

Futu NewsNov 11 22:33 · Ratings

J.P. Morgan Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $49

Futu NewsNov 9 21:31 · Ratings